viscotears 2 mg/g øjengel
dr. gerhard mann chem.-pharm. fabrik gmbh - carbomer - øjengel - 2 mg/g
viscotears 2 mg/g øjengel
orifarm a/s - carbomer - øjengel - 2 mg/g
viscotears 2 mg/g øjengel
paranova danmark a/s - carbomer - øjengel - 2 mg/g
viscotears 2 mg/g øjengel, enkeltdosisbeholder
dr. gerhard mann chem.-pharm. fabrik gmbh - carbomer - øjengel, enkeltdosisbeholder - 2 mg/g
viscotears 2 mg/g øjengel
2care4 aps - carbomer - øjengel - 2 mg/g
visc-ophtal 2 mg/g øjengel
orifarm a/s - carbomer - øjengel - 2 mg/g
tafinlar
novartis europharm limited - dabrafenib mesilate - melanom - antineoplastiske midler - melanomadabrafenib as monotherapy or in combination with trametinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600 mutation (see sections 4. 4 og 5. adjuverende behandling af melanomadabrafenib i kombination med trametinib er angivet for den adjuverende behandling af voksne patienter med stadium iii melanom med en braf v600 mutation, efter komplet resektion. non-small cell lung cancer (nsclc)dabrafenib in combination with trametinib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a braf v600 mutation.
koselugo
astrazeneca ab - selumetinib sulfate - neurofibromatosis 1 - antineoplastiske midler - koselugo as monotherapy is indicated for the treatment of symptomatic, inoperable plexiform neurofibromas (pn) in paediatric patients with neurofibromatosis type 1 (nf1) aged 3 years and above.
kerendia
bayer ag - finerenone - renal insufficiency, chronic; diabetes mellitus, type 2 - agenter, der virker på renin-angiotensinsystemet - kerendia is indicated for the treatment of chronic kidney disease (stage 3 and 4 with albuminuria) associated with type 2 diabetes in adults.
wakix
bioprojet pharma - pitolisant - narkolepsi - andre narkotika stoffer - wakix is indicated in adults, adolescents and children from the age of 6 years for the treatment of narcolepsy with or without cataplexy (see also section 5.